PL2440558T3 - Związki dihydropirolonaftyrydynony jako inhibitory JAK - Google Patents
Związki dihydropirolonaftyrydynony jako inhibitory JAKInfo
- Publication number
- PL2440558T3 PL2440558T3 PL10725338T PL10725338T PL2440558T3 PL 2440558 T3 PL2440558 T3 PL 2440558T3 PL 10725338 T PL10725338 T PL 10725338T PL 10725338 T PL10725338 T PL 10725338T PL 2440558 T3 PL2440558 T3 PL 2440558T3
- Authority
- PL
- Poland
- Prior art keywords
- dihydropyrrolonaphtyridinone
- jak
- inhibitors
- compounds
- dihydropyrrolonaphtyridinone compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18515709P | 2009-06-08 | 2009-06-08 | |
| EP10725338.7A EP2440558B1 (en) | 2009-06-08 | 2010-06-08 | Dihydropyrrolonaphtyridinone compounds as inhibitors of jak |
| PCT/US2010/037822 WO2010144486A1 (en) | 2009-06-08 | 2010-06-08 | Dihydropyrrolonaphtyridinone compounds as inhibitors of jak |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2440558T3 true PL2440558T3 (pl) | 2015-10-30 |
Family
ID=42805991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10725338T PL2440558T3 (pl) | 2009-06-08 | 2010-06-08 | Związki dihydropirolonaftyrydynony jako inhibitory JAK |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8420816B2 (pl) |
| EP (1) | EP2440558B1 (pl) |
| JP (1) | JP5719840B2 (pl) |
| CN (1) | CN102459267B (pl) |
| CA (1) | CA2764885C (pl) |
| DK (1) | DK2440558T3 (pl) |
| ES (1) | ES2540964T3 (pl) |
| HR (1) | HRP20150701T1 (pl) |
| HU (1) | HUE026518T2 (pl) |
| PL (1) | PL2440558T3 (pl) |
| PT (1) | PT2440558E (pl) |
| SI (1) | SI2440558T1 (pl) |
| SM (1) | SMT201500156B (pl) |
| WO (1) | WO2010144486A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012078802A1 (en) | 2010-12-08 | 2012-06-14 | Takeda Pharmaceutical Company Limited | PREPARATION OF SUBSTITUTED-4,5-DIHYDROPYRROLO[4,3,2-de][2,6]NAPHTHYRIDIN-3(1H)-ONES |
| KR101433057B1 (ko) * | 2012-03-07 | 2014-09-23 | 한국과학기술원 | 빛에 의해 ｒｔｋ 신호전달을 활성화하는 융합단백질 및 그의 용도 |
| KR101836822B1 (ko) * | 2016-10-17 | 2018-03-09 | 주식회사 엔지켐생명과학 | 모노아세틸디아실글리세롤 화합물을 함유하는 건선의 예방 또는 치료용 조성물 |
| EP3305786A3 (de) | 2018-01-22 | 2018-07-25 | Bayer CropScience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| CN110016030B (zh) * | 2019-05-22 | 2021-02-09 | 南京合巨药业有限公司 | 一种5-氟-1H-吡咯-[2,3-b]吡啶-4-甲醛的制备方法 |
| CN112390799B (zh) * | 2019-08-16 | 2022-04-29 | 科岭源生物科技(深圳)有限公司 | 一种含氮杂环类5-ht3受体调节剂及其制备方法和用途 |
| WO2022110052A1 (zh) * | 2020-11-27 | 2022-06-02 | 科岭源生物科技(深圳)有限公司 | 一种含氮杂环类5-ht3受体调节剂及其制备方法和用途 |
| US11561787B2 (en) | 2021-05-13 | 2023-01-24 | International Business Machines Corporation | Application invocation on specified operating system version |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3177271D1 (de) | 1980-04-11 | 1992-03-19 | Ampex | Umstellungsspeicher fuer bildwandlersystem. |
| US4437207A (en) | 1982-06-24 | 1984-03-20 | Ross Henry M | Magnetic, force-limited apparatus for tenderizing meat |
| HU187583B (en) | 1983-04-14 | 1986-01-28 | Duna-Tisza Koezi Allami Epitoeipari Vallalat,Hu | Method and apparatus for in-situ producing non-uniform pile from monolithic concrete |
| JPS6054356A (ja) | 1983-09-03 | 1985-03-28 | Taisho Pharmaceut Co Ltd | ３−ベンゾイル−２−メルカプトプロピオン酸誘導体 |
| US4526290A (en) | 1983-10-19 | 1985-07-02 | Ball Corporation | Flanged container |
| EP0193329A3 (en) * | 1985-02-22 | 1987-08-19 | Beecham Group Plc | Pyrazolopyridines, their preparation and pharmaceutical compositions containing them |
| US6600028B1 (en) * | 1997-04-02 | 2003-07-29 | Amersham Pharmacia Biotech Uk Limited | Tricyclic base analogues |
| PT1129091E (pt) | 1998-11-12 | 2003-02-28 | Neurocrine Biosciences Inc | Antagonistas de receptor de crf e metodos relacionados |
| US6531475B1 (en) | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| HUP0304035A2 (hu) | 2001-04-30 | 2004-04-28 | Glaxo Group Limited | Kortikotropin-releasing faktor (CRF) receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| KR20040018260A (ko) | 2001-05-21 | 2004-03-02 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | Ｃｒｆ 수용체 길항제로서의 트리- 및테트라아자-아세나프틸렌 유도체 |
| GB0117395D0 (en) | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
| US7273871B2 (en) * | 2001-07-17 | 2007-09-25 | Sb Pharmco Puerto Rico Inc. | Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists |
| US7049303B2 (en) * | 2001-11-07 | 2006-05-23 | Medical Research Council | Inhibition of viruses |
| WO2003061385A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents |
| AU2003224257A1 (en) | 2002-04-09 | 2003-10-27 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
| WO2005065150A2 (en) | 2003-12-19 | 2005-07-21 | Koronis Pharmaceuticals, Inc. | Mutagenic heterocycles |
| CN1925855B (zh) | 2003-12-19 | 2010-06-16 | 普莱希科公司 | 开发Ret调节剂的化合物和方法 |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| EP2298770A1 (en) * | 2005-11-03 | 2011-03-23 | ChemBridge Corporation | Heterocyclic compounds as TrkA modulators |
| WO2008079521A2 (en) * | 2006-11-01 | 2008-07-03 | Vertex Pharmaceuticals Incorporated | Tricyclic heteroaryl compounds useful as inhibitors of janus kinase |
| TWI630207B (zh) | 2005-12-13 | 2018-07-21 | 英塞特控股公司 | 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 |
| CN101460499A (zh) * | 2006-04-05 | 2009-06-17 | 沃泰克斯药物股份有限公司 | 可用作janus激酶抑制剂的去氮杂嘌呤 |
| GB0619926D0 (en) | 2006-10-09 | 2006-11-15 | Koolmill Systems Ltd | Surface abrasion of objects |
| WO2008084861A1 (ja) | 2007-01-12 | 2008-07-17 | Astellas Pharma Inc. | 縮合ピリジン化合物 |
| WO2008100447A2 (en) | 2007-02-09 | 2008-08-21 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
| WO2008112217A1 (en) * | 2007-03-13 | 2008-09-18 | Merck & Co., Inc. | Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 |
| WO2008119792A1 (en) * | 2007-04-02 | 2008-10-09 | Palau Pharma, S. A. | Pyrrolopyrimidine derivatives as jak3 inhibitors |
| TW200908968A (en) | 2007-05-29 | 2009-03-01 | Sgx Pharmaceuticals Inc | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators |
| EP2002836B1 (en) | 2007-05-31 | 2010-10-20 | Nerviano Medical Sciences S.r.l. | Cyclocondensed azaindoles active as kinase inhibitors |
| AU2008300026A1 (en) * | 2007-09-11 | 2009-03-19 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| JP2011500806A (ja) * | 2007-10-25 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
-
2010
- 2010-06-08 CN CN201080032853.3A patent/CN102459267B/zh active Active
- 2010-06-08 WO PCT/US2010/037822 patent/WO2010144486A1/en not_active Ceased
- 2010-06-08 HR HRP20150701TT patent/HRP20150701T1/hr unknown
- 2010-06-08 PT PT107253387T patent/PT2440558E/pt unknown
- 2010-06-08 US US12/796,583 patent/US8420816B2/en active Active
- 2010-06-08 CA CA2764885A patent/CA2764885C/en active Active
- 2010-06-08 JP JP2012514236A patent/JP5719840B2/ja active Active
- 2010-06-08 DK DK10725338.7T patent/DK2440558T3/en active
- 2010-06-08 HU HUE10725338A patent/HUE026518T2/en unknown
- 2010-06-08 PL PL10725338T patent/PL2440558T3/pl unknown
- 2010-06-08 ES ES10725338.7T patent/ES2540964T3/es active Active
- 2010-06-08 EP EP10725338.7A patent/EP2440558B1/en active Active
- 2010-06-08 SI SI201030965T patent/SI2440558T1/sl unknown
-
2013
- 2013-03-06 US US13/787,514 patent/US8785429B2/en active Active
-
2015
- 2015-07-01 SM SM201500156T patent/SMT201500156B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2440558T1 (sl) | 2015-10-30 |
| US20110136780A1 (en) | 2011-06-09 |
| US20130184252A1 (en) | 2013-07-18 |
| JP2012529437A (ja) | 2012-11-22 |
| EP2440558B1 (en) | 2015-04-01 |
| WO2010144486A1 (en) | 2010-12-16 |
| DK2440558T3 (en) | 2015-07-06 |
| EP2440558A1 (en) | 2012-04-18 |
| ES2540964T3 (es) | 2015-07-15 |
| CN102459267B (zh) | 2014-11-26 |
| HUE026518T2 (en) | 2016-06-28 |
| PT2440558E (pt) | 2015-08-27 |
| CN102459267A (zh) | 2012-05-16 |
| JP5719840B2 (ja) | 2015-05-20 |
| SMT201500156B (it) | 2015-09-07 |
| US8785429B2 (en) | 2014-07-22 |
| HK1167654A1 (en) | 2012-12-07 |
| HRP20150701T1 (hr) | 2015-08-28 |
| CA2764885A1 (en) | 2010-12-16 |
| CA2764885C (en) | 2018-05-15 |
| US8420816B2 (en) | 2013-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274422B (en) | Processes for preparing intermediates for protein tyrosine kinase inhibitors | |
| ZA201700326B (en) | Inhibitors of beta-secretase | |
| IL212444A0 (en) | Pyrazolylaminopyridines as inhibitors of fak | |
| IL218018A0 (en) | Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions | |
| IL219916A0 (en) | Imidazopyridine derivatives as jak inhibitor | |
| ZA201204959B (en) | Pyrazole derivatives as jak inhibitors | |
| ZA201208125B (en) | Pyrazole compounds as jak inhibitors | |
| EP2249650A4 (en) | ANILINOPYRIDINE AS A FAK HEMMER | |
| ZA201006719B (en) | Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases | |
| ZA201206410B (en) | Polyheterocylic compounds highly potent as hcv inhibitors | |
| SI2510089T1 (sl) | Sinteza prazolnih spojin | |
| EP2438246A4 (en) | CONSTRUCTION ASPECTS | |
| ZA201206456B (en) | Uses of dgati inhibitors | |
| EP2519508A4 (en) | METALLO ENZYME INHIBITOR COMPOUNDS | |
| PL2440558T3 (pl) | Związki dihydropirolonaftyrydynony jako inhibitory JAK | |
| SG10201404913QA (en) | Inhibitors of cognitive decline | |
| IL217833A0 (en) | Inhibitors of cognitive decline | |
| IL217756A0 (en) | Inhibitors of jnk | |
| GB0922023D0 (en) | Preparation of n-monofluoroalkyl compounds | |
| IL213935A0 (en) | Novel heterocyclic compounds as metap-2 inhibitors | |
| IL215486A0 (en) | Compositions of cholinesterase inhibitors | |
| GB0908609D0 (en) | New use of isoQC inhibitors | |
| GB0913427D0 (en) | Compounds for treatment of imflammation | |
| GB0905280D0 (en) | Novel uses of VEGFxxxb | |
| GB0903651D0 (en) | Inhibitors of glyoxalase |